HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Donald Francis Selected Research

AIDSVAX

3/2014Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.
4/2013Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
8/2012Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
7/2012Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Donald Francis Research Topics

Disease

7Infections
01/2017 - 08/2012
2HIV Infections (HIV Infection)
03/2014 - 07/2012
1Disease Progression
04/2013
1Acquired Immunodeficiency Syndrome (AIDS)
11/2007

Drug/Important Bio-Agent (IBA)

5VaccinesIBA
03/2014 - 11/2007
4AIDSVAXIBA
03/2014 - 07/2012
4AIDSVAX B-EIBA
03/2014 - 07/2012
3Immunoglobulin A (IgA)IBA
01/2017 - 01/2013
3Immunoglobulin G (IgG)IBA
01/2017 - 01/2013
3AntibodiesIBA
12/2016 - 01/2013
1Complement System Proteins (Complement)IBA
01/2017
1Neutralizing AntibodiesIBA
01/2013
1EpitopesIBA
01/2013
1Proteins (Proteins, Gene)FDA Link
08/2012
1AIDS VaccinesIBA
07/2012
1erdosteineIBA
07/2012